Susan E Yount

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8588994/publications.pdf

Version: 2024-02-01

318942 232693 6,294 51 23 48 h-index citations g-index papers 9100 52 52 52 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Effects of patient-reported outcome assessment order. Clinical Trials, 2022, 19, 307-315.	0.7	2
2	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology, 2021, 111, 850-862.	1.2	4
3	The PROMISⓇ-Plus-Osteoarthritis of the Knee (OAK) profile measure integrates generic and condition-specific content to enhance relevance and efficiency. Journal of Clinical Epidemiology, 2021, 135, 158-169.	2.4	1
4	Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Indexâ€10 (FHNSlâ€10). Health Science Reports, 2021, 4, e401.	0.6	2
5	Financial burden and quality of life among thyroid cancer survivors. Surgery, 2020, 167, 631-637.	1.0	50
6	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS ONE, 2020, 15, e0237497.	1.1	21
7	Validation of the Functional Assessment of Cancer Therapy–Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. Cancer, 2020, 126, 3542-3551.	2.0	6
8	<p>Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ©)</p> . Patient Preference and Adherence, 2020, Volume 14, 705-715.	0.8	5
9	FACT physical wellbeing to independently predict overall survival in patients with acute myeloid leukemia Journal of Clinical Oncology, 2020, 38, 7532-7532.	0.8	O
10	Psychological Functioning in Patients With Chronic Obstructive Pulmonary Disease: A Preliminary Study of Relations With Smoking Status and Disease Impact. Nicotine and Tobacco Research, 2019, 21, 686-690.	1.4	11
11	Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System® (PROMISî) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. Quality of Life Research, 2019, 28, 3355-3362.	1.5	40
12	PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. Value in Health, 2019, 22, 537-544.	0.1	335
13	Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure. Circulation: Heart Failure, 2019, 12, e005751.	1.6	17
14	Post-thyroidectomy neck appearance and impact on quality of life in thyroid cancer survivors. Surgery, 2019, 165, 1217-1221.	1.0	38
15	Clinical factors associated with worse quality-of-life scores in UnitedÂStates thyroid cancer survivors. Surgery, 2019, 166, 69-74.	1.0	60
16	Assessment of Self-Management Treatment Needs Among COPD Helpline Callers. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 82-88.	0.7	5
17	PROMIS \hat{A}^{o} : Standardizing the patient voice in health psychology research and practice Health Psychology, 2019, 38, 343-346.	1.3	19
18	Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease. Journal of Patient-Reported Outcomes, 2019, 3, 65.	0.9	11

#	Article	IF	CITATIONS
19	MON-558 Radioiodine Is Not Associated with Quality of Life Outcomes in Early Stage Thyroid Cancer Survivors, a Matched-Pair Analysis Journal of the Endocrine Society, 2019, 3, .	0.1	O
20	Serum adipokine levels and associations with patient-reported fatigue in systemic lupus erythematosus. Rheumatology International, 2018, 38, 1053-1061.	1.5	9
21	A method to create a standardized generic and condition-specific patient-reported outcome measure for patient care and healthcare improvement. Quality of Life Research, 2018, 27, 367-378.	1.5	19
22	Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population. Surgery, 2018, 163, 205-211.	1.0	23
23	Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data. Surgery, 2018, 164, 986-992.	1.0	47
24	Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations. Surgery, 2018, 164, 546-552.	1.0	11
25	Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10 Journal of Clinical Oncology, 2018, 36, e18743-e18743.	0.8	1
26	Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I. Surgery, 2017, 162, 1270-1277.	1.0	21
27	Financial burden is associated with worse health-related quality of life in adults with multiple endocrine neoplasia type 1. Surgery, 2017, 162, 1278-1285.	1.0	17
28	Patient-Reported Outcomes in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2016, 42, 253-263.	0.8	49
29	Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung, 2016, 194, 227-234.	1.4	82
30	Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples. Journal of Clinical Epidemiology, 2016, 73, 119-127.	2.4	323
31	A patient-centered symptom monitoring and reporting system for children and young adults with cancer (SyMon-SAYS). Pediatric Blood and Cancer, 2015, 62, 1813-1818.	0.8	22
32	Development and validation of the functional assessment of cancer therapy–antiangiogenesis subscale. Cancer Medicine, 2015, 4, 690-698.	1.3	11
33	Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations. Quality of Life Research, 2015, 24, 999-1009.	1.5	20
34	A Randomized Trial of Weekly Symptom Telemonitoring in Advanced Lung Cancer. Journal of Pain and Symptom Management, 2014, 47, 973-989.	0.6	64
35	Development and validation of the functional assessment of cancer therapy: Antiangiogenesis (FACT-AntiA) Journal of Clinical Oncology, 2013, 31, e20527-e20527.	0.8	0
36	A Brief Symptom Index for Advanced Lung Cancer. Clinical Lung Cancer, 2012, 13, 14-23.	1.1	22

3

#	Article	IF	Citations
37	Development of a Conceptual Framework and Calibrated Item Banks to Measure Patient-Reported Dyspnea Severity and Related Functional Limitations. Value in Health, 2011, 14, 291-306.	0.1	33
38	Brief, Valid Measures of Dyspnea and Related Functional Limitations in Chronic Obstructive Pulmonary Disease (COPD). Value in Health, 2011, 14, 307-315.	0.1	29
39	Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 268-278.	2.3	40
40	The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 2010, 63, 1179-1194.	2.4	3,521
41	Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). Journal of Clinical Epidemiology, 2010, 63, 1195-1204.	2.4	299
42	A Conceptual Model of the Experience of Dyspnea and Functional Limitations in Chronic Obstructive Pulmonary Disease. Value in Health, 2009, 12, 1018-1025.	0.1	37
43	Evaluation of Item Candidates. Medical Care, 2007, 45, S12-S21.	1.1	632
44	Validation of the Functional Assessment of Cancer Therapyâ€"Lung Symptom Index-12 (FLSI-12). Lung Cancer, 2007, 57, 339-347.	0.9	17
45	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Quality of Life Research, 2007, 16, 1615-1626.	1.5	24
46	An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. The Journal of Supportive Oncology, 2007, 5, 381-7.	2.3	22
47	Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). The Journal of Supportive Oncology, 2006, 4, 191-9.	2.3	65
48	Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health and Quality of Life Outcomes, 2003, 1, 69.	1.0	26
49	What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation, 2003, 21, 526-535.	0.6	94
50	Methods and progress in assessing the quality of life effects of supportive care with erythropoietin therapy. Current Opinion in Hematology, 2002, 9, 234-240.	1.2	6
51	Assessment of Patient-Reported Clinical Outcome in Pancreatic and Other Hepatobiliary Cancers. Journal of Pain and Symptom Management, 2002, 24, 32-44.	0.6	80